Helix BioPharma Corp. Extends Period to Exercise Warrants
October 16 2018 - 6:03PM
Helix BioPharma Corp. (TSX, FSE: HBP) ("Helix" or the "Company"),
an immuno-oncology company developing innovative drug candidates
for the prevention and treatment of cancer, today announced that it
has received conditional approval from the Toronto Stock Exchange
(the “TSX”) to extend the exercise period of a total of 4,546,000
outstanding common share purchase warrants (the “Warrants”), all of
which are held by arm’s length parties. The Warrants were issued
pursuant to a private placement of the Company completed on
November 1, 2013, and represent approximately 4.4% of the Company’s
issued and outstanding common shares.
Each Warrant currently entitles the holder to
purchase one common share of the Company at an exercise price of
$1.61 at any time until October 31, 2018. Subject to TSX approval,
the expiry date of the Warrants will be extended by two years to
October 31, 2020. The exercise price of the Warrants will remain
unchanged at $1.61. If approved by the TSX, the effective date of
the amendment will be October 31, 2018. The Company will not
extend 122,000 warrants held directly or indirectly by insiders of
the Company.
About Helix BioPharma Corp.
Helix BioPharma Corp. is an immuno-oncology
company specializing in the field of cancer therapy. The company is
actively developing innovative products for the prevention and
treatment of cancer based on its proprietary technologies. Helix’s
product development initiatives include its novel L-DOS47 new drug
candidate and Chimeric Antigen Receptor (“CAR”) based cell
therapies. Helix is currently listed on the TSX and FSE under the
symbol “HBP”.
Investor Relations
Helix BioPharma Corp.9120 Leslie Street, Suite
205Richmond Hill, Ontario, L4B 3J9Tel: 905-841-2300Email:
ir@helixbiopharma.com
Cautionary Statements
This news release may contain forward-looking
statements and information (collectively, “forward-looking
statements”) within the meaning of applicable Canadian securities
laws, including, without limitation, those relating to Helix’s
operations and strategy, its research and development activities
and statements regarding the expected use of net proceeds of the
private placement. Forward-looking statements, which may be
identified by words including, “without limitation”, “believe”,
“subject to”, “will”, “should” “may”, “promising” and other similar
expressions, are intended to provide information about management’s
current plans and expectations.
Although Helix believes that the expectations
reflected in such forward-looking statements are reasonable, such
statements involve risks and uncertainties that may cause actual
results or events to differ materially from those anticipated and
no assurance can be given that these expectations will be realized,
and undue reliance should not be placed on such statements. Risk
factors that could cause actual results or events to differ
materially from the forward-looking statements include, without
limitation, risks inherent in Helix’s research and development
activities and those risks and uncertainties affecting the company,
as more fully described in Helix’s most recent Annual Information
Form, including under the headings “Forward-Looking Statements” and
“Risk Factors”, filed under Helix’s profile on SEDAR at
www.sedar.com (together, the “Helix Risk Factors”). Certain
material factors or assumptions are applied in making the
forward-looking statements, including, without limitation, that the
factors described in the Helix Risk Factors will not cause Helix’s
actual results or events to differ materially from the
forward-looking statements. These cautionary statements qualify all
such forward-looking statements.
Forward-looking statements and information are
based on the beliefs, assumptions and expectations of Helix’s
management on the date of this news release, and Helix does not
assume any obligation to update any forward-looking statement or
information should those beliefs, assumptions or expectations, or
other circumstances change, except as required by law.
Helix BioPharma (TSX:HBP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Helix BioPharma (TSX:HBP)
Historical Stock Chart
From Jul 2023 to Jul 2024